Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FFK0W
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,508
Award facts
- Contract value 100% obligated
- $13,507.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $13,507.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 5, 2026, with an ultimate completion date of January 6, 2026. The award was made without a set-aside designation through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026 that provides comprehensive pharmaceutical support globally.
AmerisourceBergen's DLA IDC serves as a critical supply mechanism for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, encompassing a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The company's contract history with DLA demonstrates consistent capability in fulfilling federal medical supply requirements across varying order values. RINVOQ ER (upadacitinib extended-release), supplied under this delivery order, is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, addressing critical pharmaceutical needs within military healthcare programs.
Quick answers
Who was awarded contract SPE2DR26FFK0W?
SPE2DR26FFK0W was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FFK0W worth?
The government has obligated $13,508 on SPE2DR26FFK0W.
Is contract SPE2DR26FFK0W an order under another contract?
Yes. SPE2DR26FFK0W is a delivery order under SPE2DR25D1109, an indefinite delivery contract.
Was contract SPE2DR26FFK0W competed?
The extent of competition for SPE2DR26FFK0W was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award